Drug Patent Watch

AUGUST 24, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies 52

Allergies Drugs Marketing 52

Drug Patent Watch

AUGUST 14, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies 52

Allergies Drugs Marketing 52

BioTech 365

OCTOBER 7, 2020

LONDON–(BUSINESS WIRE)–#AllergyImmunotherapiesMarket–The global allergy immunotherapies market size is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% throughout the forecast period, according to the latest report by Technavio.

Allergies 40

Allergies Marketing Research 40

pharmaphorum

OCTOBER 27, 2021

AIT involves the administration of controlled, low doses of allergens under the tongue or by subcutaneous injection in people with allergies, with the aim of desensitising the immune system to them and prevent allergic reactions. ” The post Allergy specialist Stallergenes taps Aptar for digital delivery appeared first on.

Allergies 64

Allergies Drug Delivery Development Marketing 64

BioTech 365

NOVEMBER 6, 2020

European Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Analysis – ResearchAndMarkets.com European Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Analysis – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Europe Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact (..)

Allergies 40

Allergies Marketing 40

Drug Patent Watch

AUGUST 2, 2021

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. The post New patent expiration for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF appeared first on DrugPatentWatch - Make Better Decisions.

Allergies 52

Allergies Drugs Marketing 52

BioTech 365

JULY 20, 2021

Global Allergy & Immunology Market Research Report 2021-2026: Extensive R&D for Immunotherapy Solutions Against Food Allergens – ResearchAndMarkets.com Global Allergy & Immunology Market Research Report 2021-2026: Extensive R&D for Immunotherapy Solutions Against Food Allergens – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

Allergies 40

Allergies Marketing Research 40

BioPharma Reporter

JANUARY 18, 2021

At the end of December, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) updated its advice on the Pfizer/BioNTech vaccine: saying that those with unrelated allergies could receive it. But this announcement did not receive as much coverage as the MHRAâs earlier pause on vaccination in people with allergies.

Allergies 98

Allergies Vaccination Vaccine Medicine 98

BioTech 365

NOVEMBER 25, 2020

Global Allergy Immunotherapy (AIT) Market to 2024 – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com Global Allergy Immunotherapy (AIT) Market to 2024 – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Allergy … (..)

Allergies 40

Allergies Marketing 40

BioTech 365

JUNE 14, 2021

Global Allergy Diagnostic and Treatment Market (2021 to 2029) – Featuring bioMerieux, Siemens Healthcare and Danaher Among Others – ResearchAndMarkets.com Global Allergy Diagnostic and Treatment Market (2021 to 2029) – Featuring bioMerieux, Siemens Healthcare and Danaher Among Others – ResearchAndMarkets.com … Continue (..)

Allergies 40

Allergies Marketing 40

BioTech 365

MARCH 9, 2021

Global Anti-Allergy Drugs Market Report 2021: Market to Reach $39.3 Market is Estimated at $6.7 CAGR – ResearchAndMarkets.com Global Anti-Allergy Drugs Market Report 2021: Market to … Continue reading → Billion by 2027 – U.S. Billion, While China is Forecast to Grow at 10.5%

Allergies 40

Allergies Marketing Drugs 40

BioTech 365

DECEMBER 15, 2021

Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share of More Than 25% – ResearchAndMarkets.com Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share … Continue reading →

Allergies 40

Allergies Marketing Drugs 40

Drug Patent Watch

DECEMBER 24, 2020

Annual Drug Patent Expirations for ALLEGRA-D+24+HOUR+ALLERGY+AND+CONGESTION Allegra-d 24 Hour Allergy And Congestion is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from….

Allergies 52

Allergies Drugs Marketing 52

The Pharma Data

JANUARY 7, 2021

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

Allergies 52

Allergies Manufacturing Production Clinical Trials 52

BioTech 365

AUGUST 10, 2020

SEATTLE–(BUSINESS WIRE)–#RagweedPollenAllergyTreatment–According to Coherent Market Insights, the global ragweed pollen allergy treatment market is estimated to be valued at US$ 836.9 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).

Allergies 52

Allergies Marketing 52

BioTech 365

NOVEMBER 17, 2021

The Worldwide Allergy Diagnostics Industry is Expected to Reach $8.2 Billion by 2026 – ResearchAndMarkets.com The Worldwide Allergy Diagnostics Industry is Expected to Reach $8.2

Allergies 40

Allergies Production Marketing 40

BioTech 365

OCTOBER 7, 2020

LONDON–(BUSINESS WIRE)–#AllergyRhinitisDrugsMarket–The global allergy rhinitis drugs market size is poised to grow by USD 2.4 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio.

Allergies 40

Allergies Marketing Drugs Research 40

pharmaphorum

AUGUST 5, 2020

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. The rationale behind Viaskin Peanut is to expose people with peanut allergy to small, rising amounts of peanut protein – which acts as an allergen – to encourage the immune system to develop tolerance over time.

Allergies 52

Allergies Production Clinical Trials Clinical Trials 52

STAT News

DECEMBER 5, 2022

In the fight to command the growing market for telehealth, Thirty Madison is staking out new terrain. Over the last year and a half, the 5-year-old digital health startup has been quietly planning to expand into sleep care with a new brand called River. Continue to STAT+ to read the full story…

Marketing 98

Marketing Allergies Pharmacy Branding 98

Pharmaceutical Technology

MARCH 20, 2023

The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies. RVAC Medicines chief scientific officer Dr Jason Zhang said: “We are very glad to work with Dr Weissman on potential mRNA treatment approaches for a broad spectrum of allergy and autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Pharmaceutical Technology

AUGUST 1, 2022

The company will jointly design and analyse messenger ribonucleic acid (mRNA) Covid-19 vaccines in partnership with the NIH unit National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC). They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Antidote

SEPTEMBER 1, 2023

As part of our efforts to better understand patients and their motivations to participate in clinical trials, Antidote and SCORR Marketing partnered on a survey to gain a deeper understanding of how patients think about the medical research process.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Allergies 95

Pharmaceutical Technology

MAY 16, 2023

The firm plans to offer more than 100 new products to the Canadian market in the next four years, with pain management, oral solutions, allergy vaccines, diabetes and weight loss as the main areas of focus. The deal allows Juno to provide medical practitioners and patients with new critical pharmaceutical products.

Cosmetics 130

Cosmetics Allergies Manufacturing Production 130

XTalks

SEPTEMBER 28, 2023

Related: Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate Bayer’s new over-the-counter (OTC) cold, flu and allergy med Astepro not only emerged as the most viewed new pharma TV ad in the first half of the year, but also topped iSpot.tv’s list of all new brand ads with 7.4

Drugs 105

Drugs Allergies Branding FDA Approval 105

XTalks

FEBRUARY 26, 2024

The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Antidote

NOVEMBER 20, 2023

In both 2018 and 2023, Antidote partnered with SCORR marketing to conduct surveys intended to increase the understanding of patients’ perceptions of clinical trials. Our 2018 survey collected data from nearly 4,000 individuals to gain insight into what matters most when considering a clinical trial.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Allergies 52

pharmaphorum

OCTOBER 1, 2021

The debut – raising upwards of £350 million from new shares – is the largest IPO for a UK biotech company since allergy drug specialist Circassia in 2014. The post Oxford Nanopore makes stellar debut on UK stock market appeared first on.

Marketing 52

Marketing Business Development Genome Genomics 52

XTalks

MARCH 3, 2022

Food allergies are becoming more and more common, but that doesn’t mean those with allergies can’t enjoy a sweet treat. The team is eager to try this new type of milk and wonders whether it will be the best milk alternative — in flavor, texture and appearance — when it finally hits the market. .

Allergies 98

Allergies Branding Protein Production 98

World of DTC Marketing

OCTOBER 6, 2021

Like the vast majority of medicines on the market, molnupiravir — which was originally investigated as a possible treatment for Venezuelan equine encephalitis — was developed using government funds. The Intercept. Merck is not alone in hosing taxpayers.

Clinical Trials 198

Clinical Trials Clinical Trials Allergies Trials 198

Drug Discovery World

MARCH 1, 2024

The top stories: FDA approves first medication to reduce allergic reactions The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I).

Drugs 52

Drugs Allergies FDA Approval Medicine 52

Pharmaceutical Technology

JUNE 10, 2023

Taiho Pharmaceutical overview Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, immunology, allergy and urology. It was under development for the treatment of gastric cancer and multiple myeloma.

Allergies 100

Allergies Production Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

Taiho Pharmaceutical overview Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, immunology, allergy and urology. It was under development for the treatment of gastric cancer and multiple myeloma.

Allergies 100

Allergies Production Clinical Trials Clinical Trials 100

The Pharma Data

NOVEMBER 5, 2020

“We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. annual market size for Hydroxychloroquine Sulfate Tablets, 200 mg was approximately US$237 million (IQVIA MAT June 2020 ). YARDLEY, Pa.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

The Pharma Data

JULY 11, 2021

3 These data are being presented at the 2021 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Krakow, Poland and Madrid, Spain. Depending on regional marketing authorization, TAKHZYRO is available as a 300 mg dose in a vial or pre-filled syringe. percent (-100; 852.8), and the median reduction was 97.7

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

pharmaphorum

NOVEMBER 9, 2022

AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour of approval. The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted by 16 to one that PT027 should be approved for use in adults.

Drugs 59

Drugs Allergies Marketing Trials 59

pharmaphorum

NOVEMBER 16, 2022

Novartis’ respiratory and allergy business, meanwhile, is headed by Xolair (omalizumab) for severe asthma nasal polyps and chronic idiopathic urticaria (CIA) – another blockbuster also partnered with Roche. Novartis has said it will not comment on market speculation.

Sales 124

Sales Gene Therapy Allergies Medicine 124

BioPharma Reporter

MARCH 23, 2021

The US National Institute of Allergy and Infectious Diseases (NIAID) says it is concerned that AstraZeneca 'may have included outdated informationâ when releasing initial data from its COVID-19 vaccine clinical trial.

Vaccination 52

Vaccination Vaccine Allergies Trials 52